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Introduction 
COVID-19 has brought many world-wide challenges in a very short space of time and the race to 
produce a reliable and rapid test is already on.  Currently the test of choice is a PCR method, which is 
used to detect RNA and therefore genetic information about the virus. However, like all tests there 
are limitations, this test relies on the person in question actually being infected with the virus and 
also sufficient virus being present in a swab test [1]. The aim of this commentary is to suggest breath 
analysis by mass spectrometry and specifically using mobile mass spectrometry equipment as an 
alternative testing method. Using breath as a sample, it would be possible to easily measure volatile 
organic compounds (VOCs) with mass spectrometry illustrating an alternative sampling and analysis 
technique. Breath would not only provide an unlimited sample but also allow non-invasive testing 
with the possibility of a very quick patient diagnosis by analysis with this method. Mass 
spectrometry has long been relied upon within a clinical and medical setting, so a move to using it 
for this application would be a natural step [2]. 
The RT- PCR test already available is reliable and indeed for a test to be most valuable it needs to 
able to identify the virus before any symptoms are noticeable in a patient. A test that can rapidly 
check before key workers begin work would give a huge amount of confidence to those in key roles 
undertaking stressful tasks at this time. As the RT-PCR test is used to detect the presence of an 
antigen as opposed to antibodies or the bodys immune response, these tests should be able to 
detect whether the virus is present at an early stage regardless of whether any symptoms are 
present, and as it is highly specific should allow for few false positive results. If the pattern of who is 
infected is clear, it becomes much easier to control the spread and quarantine those individuals with 
links to the virus infection as necessary. This helps Public Health bodies to monitor and limit the 
spread of the disease better which is critical to lockdown exit strategies around the world and also to 
re-booting economies. 
However these tests have not been quick enough to meet demand for testing for several reasons. 
Many hospitals do not have access to PCR machines. In the UK, several distant hubs are available 
and so samples and/or people need to be transported. PCR currently relies on experienced, trained 
staff to prepare and analyze samples. The technique potentially has a high rate of false negatives, 
which can lead to repeat testing or further tests being needed for reliable results [3].  
At present the test involves taking nasal and throat swabs which are then sent away for PCR analysis. 
Clearly there must be sufficient virus for amplification to occur. A false negative can occur for many 
reasons [3, 4]. The sample can contain too little virus because the location swabbed is not 
appropriate for the stage of infection [5] or the time taken between sampling and analysis is too 
long. Wikramaratna et al and references therein [4] showed that between day 0 and day 10 after 
infection; the chance of a positive test declined from 94.39% to 67.15%. Later in disease 
development the virus multiplies in the lungs but has disappeared from the throat. When this has 
occurred samples must be obtained from deep in the airways or coughed up sputum. After 4 weeks 
SARS can be detected in urine [6], however there is little evidence so far that COVID-19 is present in 
urine [7]. These reasons lead towards the need for an alternative or complimentary technique being 
available to medical staff and deep breath samples, which are still likely to contain biomarkers for 
the presence of the virus, maybe the solution. 
Currently the testing is done in specialist laboratories using specialist staff, which are often found in 
large cities or certainly remotely from each other. Testing is not always quickly and easily available 
remotely. More mobile methods of testing and easy sample collection would hugely increase the 
capacity to test. Some alternative options are already beginning to be used, such as serology 
methods or more automated assays, however these are in the early stages of development and 
home testing kits that are now available still need to be sent to specialist centres for analysis [8]. 
Targets for testing still need to be increased and made more universally available. 
Testing is clearly a necessary objective as countries where the track testing of individuals was 
introduced early, the benefits have been clearly observed. For instance South Korea who introduced 
a test and contact tracing promptly have a much lower percentage death rate, around 0.9% per case 
than the WHO estimation of 3% globally [9]. However mass testing of populations is not always easy 
and also depends upon many other environmental factors such as the dynamics of the country, age 
profile and density of population, which all contribute to the spread and severity of the disease. 
Methodology 
The PCR test relies on a swab being taken and particularly on the quality of sample obtained. This 
should ideally be from the upper respiratory tract with samples of sputum, a mixture of saliva and 
mucus coughed up from the respiratory tract [10]. Could a simple breath test be a quicker and easier 
way of sampling as it would be easier to take several replicate samples at the same time? 
Breath analysis 
Breath analysis is already well publicised as a suitable sample for the analysis of biomarkers for 
disease and has been suggested as a suitable sample for detection of COVID-19 [11]. Various breath 
sampling devices are available such as BioVOC tubes. These are non-invasive methods of sampling 
and allow for non-medically trained staff to take the samples [12]. Samples can easily be transferred 
from the tubes to thermal desorption tubes (TD), SPME or a needle trap device for analysis by GC-
MS. TD-GC-MS is already a standardized way of analyzing volatiles in breath and allows for a set 
amount of gas to be absorbed onto the tube during sampling and desorbed off the tube during 
analysis. Therefore TD-GC-MS provides a method that can concentrate the sample from a known 
volume of breath and provide a quantitative result. [13]. The recent emergence of portable mass 
spectrometry equipment could enhance the capability of testing as it can be easily moved as 
needed. Sampling using solid-phase microextraction (SPME) syringes or needle trap devices that 
could be analyzed by portable GC-MS devices would allow for a rapid analysis, but even sampling 
using more traditional thermal desorption tubes (TD) would still allow for easy transfer of samples 
onto SPME or needle trap syringes. These methods are already well standardized and characterized. 
Previous studies on various breath sampling methods include that by Lawal et al, who implemented 
an in-depth study into different breath analysis methods [14], although at present no absolute 
standard exists.  
Location of testing 
One of the key questions is whether breath analysis should be carried out within a laboratory setting 
with samples shipped and possibly stored before analysis, but this would not give much more of an 
advantage to this methodology over the current PCR method. With the advent of portable mass 
spectrometry, it would make more sense to have the equipment in hospitals, GP surgeries and 
testing centres and even in airports. It may also be installed in care homes that are particularly 
vulnerable to the virus and other such locations, and where it would be efficient to do so, kept in a 
vehicle and transported from one location to another. Mass spectrometers could provide answers in 
seconds rather than the hours of the current methods. The availability of breath-sample collectors 
and the ease of use of portable mass spectrometers that can be programmed to look for a 
biomarker or suite of biomarkers would make it very accessible to non-specialist users and allow 
rapid result turnovers, with the possibility of quick further analysis if the result is unclear. This point-
of-care approach would be a huge step forward in an increase of testing. The cost-effectiveness of 
this point-of-care model would need to be taken into consideration. 
Analytical requirements 
One of the key aims would be to make sure the volatile components are at a high enough 
concentration as generally VOCs are only a small percentage of breath as compared to CO2. In 2018 
Hanna et al. conducted a systematic review of breath in relation to the diagnosis of cancer. This 
suggested that multicenter clinical trials for cancer diagnosis which involved standardised methods 
of breath collection were required [15].  Another recent study into breath analysis as a means of 
identifying cancer concluded that the main advantages of breath analysis was that it was non-
invasive, it was easy to use, it had prognostic abilities, and it was low cost. However it is 
acknowledged that it may not yet be a stand-alone diagnostic method and may benefit from being 
used in combination with currently available methods to increase the accuracy of detection [16].  
SPME as an approach 
SPME has several advantages for sampling volatiles from breath; varying levels of moisture do not 
alter the absorption of volatiles onto the fibres, the volatiles are concentrated in one simple step, 
the sample can be placed directly into the GC-MS. It is also very cost effective as the SPME fibres can 
be used multiple times The analysis can be done manually using portable equipment or automated 
using static laboratory equipment. Aksenov et al. used various different SPME technologies to 
illustrate the wide coverage of breath metabolites that could be measured by the combination of 
SPME and GC-MS [17]. Biomarkers for disease are known to be present in breath [18] and SPME has 
already been used to detect lung infections [19]. The Torion T9 GC/MS is a portable machine 
(weighing 15kg) that will be ready to analyse samples within 15 minutes of starting up and provides 
an analysis time of a few minutes. It can be programmed to automatically identify biomarkers of 
interest allowing a non-specialist to run the analysis. Therefore the result can be obtained while the 
patient waits and where there is doubt about the result a second sample can easily be obtained. As 
portable mass spectrometers have their own integral gas supply, pump and batteries the equipment 
needs no specialist services for operation. Thus rather than shipping samples the equipment itself 
can be taken to the patients e.g., in care homes. 
 
Discussion  
Exhaled breath contains thousands of VOCs, which may include not only exhaled products but also 
remnants of the virus itself. To be able to analyse these routinely a metabolomics approach needs to 
be taken to understand the distribution of metabolites within the samples and to be able to identify 
significant biomarkers. Breath analysis has routinely been used for detection of alcohol in breath but 
also in more clinical settings. To assess exposure to the biomarkers medical staff could wear thermal 
desorption tubes. This procedure is already used by veterinary nurses who are exposed to nitrous 
oxide on a regular basis. Exposure is then measured by GC-MS analysis [20]. Once reliable 
biomarkers have been established the level of hazard to infection could be monitored in wards. If 
thermal desorption tubes were used for the monitoring the amount of exposure and the pattern 
over time in relation to the number of patients in the ward could be established. Otherwise an 
exhaled breath container could be used. Work has already demonstrated that breath exhaled from 
patients with pneumonia show an altered metabolism for volatile organic compounds [21]. As 
COVID-19 appears to affect the lungs, particularly if the patient has damaged lungs already through 
smoking or COPD, these patients are more at risk. 
For home collection of samples, it would be much easier for a non-specialist to take samples by 
exhaling into a container even if multiple samples were needed, rather than the current sampling 
technique of taking a single swab of the throat and nose. This is because the best area to swab may 
change depending upon the stage of infection. A recent study found that nasopharyngeal swabs may 
be more suitable at later stages of infection than oropharyngeal swabs [22]. 
The key would be whether there is a particular biomarker that indicates the presence of the virus or 
whether it is a suite of metabolites and how early a change in metabolism can be identified. To this 
end work has already begun on a Human Breath Database , which could help define key markers 
[23]. Using a library-based system with a particular list of biomarkers as targets could provide an 
easy yes or no answer or recommend further testing with swabs collected for analysis by PCR. The 
ability to automate analysis, the lack of a need for a specialist, the simplicity of the system and its 
portability would allow rapid expansion in capacity of testing. As indicated previously GC-MS is 
already used for medical analysis and therefore the equipment would already be available for many 
other uses. The advantage of mass spectrometry is that it could highlight more than one problem 
with the same sample. 
Conclusion 
There is much evidence that breath analysis may well be suitable for the analysis of biomarkers. 
Breath represents a non-invasive, limitless sample that when combined with fast, portable mass 
spectrometry methods would make an alternative or complimentary test to the PCR test already 
available. 
Although sample uniformity may need to be addressed the limitless supply of breath is suitable for 
taking multiple samples and, thus, allowing replication and reducing the likelihood of false positive 
results like an A and B sample in drug testing procedures currently. Sampling of breath is likely to be 
much less problematic than swab testing particularly for home sample collection kits due to the 
fiddly nature of collecting the sample and the importance of avoiding any contamination on the 
swab from other germs. Evidence is already showing that depending on the stage of infection with 
the virus that swab tests may not always be the best test [24].  
Mass spectrometry is already being used for breath analysis. The key would be to find biomarkers 
related to COVID-19 and to understand the variability and reproducibility of mass spectrometry 
analysis of breath samples infected with COVID-19 and to make sure that any biomarkers were 
identified with a statistical confidence. Translation of these findings to a routine analysis should be 
fast. 
Studies able to rapidly transpose mass spectrometry-based breath analysis, using cases at different 
stages of disease along with controls, from the lab to a clinical setting are what is needed to take this 
forward. 
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